Plain-English translation of NCT03445949 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After you have a procedure to close a small pouch in your heart (called the left atrial appendage) using a special device, doctors aren't sure how long you should take blood-thinning medications to prevent blood clots and strokes. This trial compares two different lengths of treatment with dual antiplatelet therapy (two blood-thinning medications taken together) followed by different durations of single-medication treatment, to find out what works best and is safest.
While this heart-closure procedure is proven to prevent strokes in people with irregular heartbeats, doctors don't yet have clear guidelines about how long patients should stay on blood thinners afterward. Finding the optimal treatment length could reduce both dangerous blood clots and bleeding complications, and help guide future medical recommendations.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of four groups that differ in how long you take two blood-thinning medications together (either 30 days or 6 months) and how long you continue a single medication afterward (either stopping completely or continuing long-term). You'll have follow-up visits and imaging tests over 18 months to check for blood clots, bleeding, and how well your device is working. The study involves medical visits, blood tests, and heart imaging to monitor your safety and health throughout the treatment period.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Poland